---
schema_version: "secwatch.filing_event.v1"
accession: "0001689375-26-000027"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:51:17.936266+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Entrada reports positive Phase 1/2 data for ENTR-601-44 in DMD; Q1 net loss $39.7M

## Summary
- Cohort 1 of ELEVATE-44-201 met primary safety endpoint: no SAEs, no discontinuations, kidney markers normal.
- Statistically significant improvement in Time to Rise velocity versus placebo (p<.05), 3.5x MCID threshold.
- Dystrophin increased 2.36% over 4.00% baseline; exon skipping increased 2.31% over 2.66% baseline.
- Cash, cash equivalents and marketable securities $254.9M as of March 31, 2026; runway into Q3 2027.
- Q1 net loss $39.7M vs $17.3M in Q1 2025; collaboration revenue dropped to $0.9M from $20.6M.

## SEC filing metadata
- accession: 0001689375-26-000027
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000168937526000027/0001689375-26-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000168937526000027/trda-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689375-26-000027
- JSON: https://secwatch.observer/filing/0001689375-26-000027.json
- Plain text: https://secwatch.observer/filing/0001689375-26-000027.txt

## Key facts
- Earnings Releases
  Entrada Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.
  - Period: the first quarter ended March 31, 2026
  - Result: reported results
  source text: On May 7, 2026, Entrada Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026 and other corporate updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1689375/000168937526000027/0001689375-26-000027-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.